OakChart

Aytu BioPharma Inc

AYTUHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.810.00 (0.00%)
2026-11-12 03:34 CET
Market cap
19.67 USD m
Revenue, TTM
57.57 USD m
Net income, TTM
-14.25 USD m
Free cash flow, TTM
3.25 USD m
EPS diluted, TTM
-1.67
P/E
-
Compare

Price

AYTU against its 20, 50 and 200-day averages
2050200beatearnings
1.802.002.202.402.60139K278KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AYTUclose 1.8120-day 1.9250-day 2.03200-day 2.281.8152w low

40.9% under the 52-week high of 3.07 on 5 Jan 2026. 52-week low 1.75 on 5 Nov 2026. Last 15 sessions, 15.4% high to low

Volume 0.33× normal · the line is the 50-bar volume average

Profile

AYTU
52-week range, 5% of the way up
1.753.07

Aytu BioPharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. Its products include EXXUA, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, and Metadate CD. The company was founded on August 9, 2002 and is headquartered in Denver, CO.

Employees76
IPOSep 24, 2008
Beta0.22
ATR, 14d0.10
Rel volume0.33
Short float3.03%
Insider own8.26%
Inst own35.61%

Snapshot

6 groups

Valuation

Index-
Market Cap19.67M
Enterprise Value11.47M
Income-14.25M
Sales57.57M
Book/sh3.29
Cash/sh2.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees76
IPOSep 24, 2008

Ratios

P/E-
Forward P/E6.70
PEG-
P/S0.34
P/B0.55
P/C0.75
P/FCF6.05
EV/EBITDA-
EV/Sales0.20
Quick Ratio1.00
Current Ratio1.13
Debt/Eq0.51
LT Debt/Eq0.28
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.67
EPS next Y0.27
EPS next Q-0.26
EPS this Y46.26%
EPS next Y143.32%
EPS next 5Y-
EPS past 3/5Y39.03% 55.93%
Sales past 3/5Y-18.77% -2.59%
EPS Y/Y TTM27.11%
Sales Y/Y TTM-13.27%
EPS Q/Q99.97%
Sales Q/Q6.42%
EarningsNov 16 AMC
EPS/Sales Surpr.100.00% 31.20%

Ownership

Insider Own8.26%
Insider Trans0.00%
Inst Own35.61%
Inst Trans-4.61%
ROA-12.41%
ROE-52.55%
ROIC-31.51%
Gross Margin59.62%
Oper. Margin-12.57%
Profit Margin-24.76%
SMA20-5.75%
SMA50-10.96%
SMA200-20.75%
Trades-

Technical

Shs Outstand10.73M
Shs Float9.97M
Short Float3.03%
Short Ratio8.71
Short Interest0.30M
52W High3.07 -40.95%
52W Low1.75 3.43%
Volatility7.97% 5.52%
ATR (14)0.10
RSI (14)35.74
Beta0.22
Rel Volume0.33
Avg Volume34.64K
Volume11,443

Performance

Perf Week-5.73%
Perf Month-9.05%
Perf Quarter-21.30%
Perf Half Y-19.56%
Perf YTD-30.38%
Perf Year-13.81%
Perf 3Y-37.80%
Perf 5Y-96.26%
Perf 10Y-100.00%
Recom1.00
Target Price9.67
Prev Close1.81
Price1.81
Change %0.00%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Jul 01, 2025InitiatedLLake StreetBuy$8+342.0%
Jun 30, 2025InitiatedAAscendiant Capital MarketsBuy$12+563.0%
Mar 30, 2021InitiatedCCantor FitzgeraldOverweight$11+507.7%
May 29, 2020InitiatedHH.C. WainwrightBuy$3+65.7%

Peers

Mkt cap
TickerCompanyMkt cap
SUPNSupernus Inc6.12B
CINGCingulate Inc67.47M
CPIXCumberland Pharmaceuticals Inc91.70M
DERMJourney Medical Corp125.31M
AXSMAxsome Therapeutics Inc7.85B
SCLXScilex Holding Company11.40M
VNDAVanda Pharmaceuticals Inc250.95M
TNXPTonix Pharmaceuticals Holding Corp75.20M
ZVRAZevra Therapeutics Inc705.13M
RLMDRelmada Therapeutics Inc472.55M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 99
  • Aytu's Exua Ramp Faces Its First Real Test As Seasonal Spending Squeezes Near-Term Profits (Earnings Whispers)
  • Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026 (ACCESSWIRE)
  • Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ... (GuruFocus.com)
  • Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results (ACCESSWIRE)
  • Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 (ACCESSWIRE)
  • Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 (ACCESSWIRE) -6.11%
  • Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 (ACCESSWIRE)
  • Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ... (GuruFocus.com)
  • Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results (ACCESSWIRE)
  • Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 (ACCESSWIRE)
  • Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -10.31%
  • Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
  • Aytu BioPharma AYTU Q2 2026 Earnings Transcript (Motley Fool)
  • Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2027Q12026-11-16--0.257--13.273
2026Q42026-09-220.000-0.2900.00016.1112.283
2026Q32026-05-13-0.530-0.443-0.53512.4112.053
2026Q22026-02-03-1.050-0.407-1.05515.2012.173
2026Q12025-11-13-0.080-0.190-0.07713.8912.603
2025Q42025-09-23-2.930-0.033-2.91815.1417.923
2025Q32025-05-140.200-0.1700.21118.4513.741
2025Q22025-02-12-0.280-0.280-0.26316.2215.551
2025Q12024-11-13-0.200-0.3400.16216.5713.771
2024Q42024-09-26-0.820-0.450-0.82417.9818.301
2024Q32024-05-15-0.520-0.640-0.52217.9917.351
2024Q22024-02-14-0.040-0.250-0.04022.9321.751
2024Q12023-11-14-1.480-0.040-1.48122.1027.731
2023Q42023-09-27-0.590-0.950-0.59330.7327.691
2023Q32023-05-11-1.930-0.630-1.93222.7028.001
2023Q22023-02-21-2.150-0.700-43.03826.2829.502

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-3,062--3,0613.66-
2019FY-696-430-696.187.327.38
2020FY-60.000-44.000-60.28027.6324.03
2021FY-69.600-56.800-69.61365.6366.15
2022FY-75.000-66.600-1,48096.6794.90
2023FY-5.110-6.160-5.105107.4104.36
2024FY-2.860-2.490-2.86181.0081.33
2025FY-2.2600.337-2.16066.3869.15
2026FY-1.160-1.060-1.16057.5753.75
2027FY--0.623--67.91
2028FY-0.270--86.91
2029FY-1.600--116.24

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2026-09-2930113.2712.3014.50
2027Q1S2026-09-2320012.6612.3013.01
2027Q1S2026-09-2210017.1817.1817.18
2027Q1S2026-05-1410017.1817.1817.18
2027Q1S2026-02-2110017.1817.1817.18
2027Q1S2026-02-0411017.1817.1817.18
2027Q1S2025-12-0811017.1817.1817.18
2027Q1S2025-11-1410015.9715.9715.97
2027Q1S2025-11-1110015.9715.9715.97
2027Q1S2025-11-1010015.9715.9715.97
2027Q1S2025-11-0910015.9715.9715.97
2027Q1S2025-11-0810015.9715.9715.97
2027Q1S2025-11-0710015.9715.9715.97
2027Q1S2025-11-0610015.9715.9715.97

Estimate history

EPS, annual-3061.24-696.182-60.28-69.613-1480.112-5.105-2.861-2.16-1.157
Period201820192020202120222023202420252026
EPS, quarterly-0.8240.162-0.2630.211-2.918-0.077-1.055-0.535-0.001
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual3.667.3227.63265.63296.669107.39965.18366.38257.57
Period201820192020202120222023202420252026
Sales, quarterly17.97616.57416.22118.45215.13513.88815.16512.41116.106
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual0.0090.0880.6291.3750.0965.5175.9738.97710.728
Period201820192020202120222023202420252026
Shares, quarterly5.9736.1496.176.178.9779.91210.73310.73310.728
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue57.5757.5766.3865.18107.4096.6765.6327.637.32
Cost of Goods Sold Incl. D&A23.2423.2424.2319.8145.5550.2342.4412.774.34
Gross Profit34.3334.3342.1545.3761.8446.4423.1914.862.98
Selling, General and Administrative Excl. Other41.5642.6439.6144.8174.1782.5461.4332.7819.26
Research and Development-0.001.332.774.0912.665.621.720.59
Other Operating Expense0.000.000.000.000.002.000.000.000.00
Operating Income-7.24-8.312.540.56-12.33-38.10-38.24-17.92-16.28
Interest Expense1.901.903.705.06----0.00
Unusual Expense0.000.0010.362.754.7471.6317.74-6.9110.32
Net Income Before Taxes-14.23-14.23-13.74-10.38-17.05-108.89-58.03-13.62-27.13
Income Taxes0.020.020.442.140.00-0.110.260.000.00
Consolidated Net Income-14.25-14.25-14.18-12.52-17.05-108.78-58.29-13.62-27.13
Net Income From Continuing Operations-14.25-14.25-14.18-12.52-17.05-108.78-58.29-13.62-27.13
Net Income-14.25-14.25-13.56-15.84-17.05-108.78-58.29-13.62-27.13
EPS (Recurring)-0.92-1.16-1.00-2.51-4.11-797.83-54.78-81.67-510.82
EPS (Basic, Before Extraordinaries)-1.38-1.16-2.16-2.86-5.11-1,480.11-69.61-60.28-696.18
EPS (Diluted)-1.67-1.16-2.16-2.86-5.11-1,480.11-69.61-60.28-696.18
EBITDA-3.31-4.387.917.29-3.51-27.96-30.54-13.33-14.04
Non-Operating Income (Expense)-5.10-4.02-2.21-3.130.010.85-2.05-2.61-0.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.630.550.462.306.054.152.611.081.02
Price To Sales Ratio0.720.460.210.250.050.011.282.322.01
Gross Margin59.6259.6263.4969.6157.5848.0435.3353.7840.74
Operating Margin-12.57-14.443.820.87-11.48-39.42-58.26-64.86-222.35
Net Margin-24.76-24.76-20.43-24.31-15.88-112.53-88.81-49.29-370.64
Shares Outstanding10.7310.738.985.975.520.101.370.630.09
Market Capitalization19.6719.6713.4517.446.0526.62137.73178.6924.28

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue16.1112.4115.1613.8915.1318.4516.2216.57
Cost of Goods Sold Incl. D&A6.465.576.075.155.806.576.365.51
Gross Profit9.656.849.108.749.3311.899.8711.06
Selling, General and Administrative Excl. Other9.3510.9011.0710.258.699.4610.2411.21
Research and Development-0.000.000.000.220.160.520.43
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.30-4.06-1.97-1.500.642.42-0.38-0.15
Interest Expense0.380.440.560.520.730.901.080.99
Unusual Expense0.000.000.000.008.260.001.320.78
Net Income Before Taxes-0.00-5.61-10.581.97-19.443.820.381.50
Income Taxes0.010.010.000.000.44-0.12-0.280.41
Consolidated Net Income-0.01-5.62-10.581.97-19.883.940.671.09
Net Income From Continuing Operations-0.01-5.62-10.581.97-19.883.940.671.09
Net Income-0.01-5.62-10.581.97-19.823.990.791.47
EPS (Recurring)-0.00-0.53-1.05-0.08-2.070.21-0.150.22
EPS (Basic, Before Extraordinaries)-0.00-0.53-1.050.21-2.920.650.130.24
EPS (Diluted)-0.00-0.53-1.05-0.08-2.920.21-0.260.16
EBITDA1.42-2.94-1.08-0.701.933.740.961.28
Non-Operating Income (Expense)0.08-1.11-8.053.98-11.092.303.163.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.120.120.280.110.090.110.120.14
Price To Sales Ratio0.720.510.420.570.220.140.210.28
Gross Margin59.9055.1059.9962.9561.6764.4260.8266.76
Operating Margin1.87-32.75-12.99-10.834.2313.12-2.33-0.88
Net Margin-0.09-45.27-69.7914.15-130.9421.654.868.89
Shares Outstanding10.7310.7310.739.918.986.176.176.15
Market Capitalization19.6729.3026.4918.6313.457.4010.4514.04

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments26.3130.9520.0122.9819.3649.9048.3311.297.11
Short Term Receivables22.7831.1623.5328.9421.7128.205.631.740.58
Inventories6.8611.4312.1411.9910.8516.3410.001.441.34
Other Current Assets5.815.646.228.918.0110.8011.460.960.44
Total Current Assets61.7679.1861.8972.8359.93105.2375.4215.439.47
Net Property, Plant & Equipment1.241.591.523.876.308.700.890.200.22
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets41.4042.2052.4558.9770.63151.2776.9419.0811.37
Deferred Tax Assets0.400.250.761.38-10.911.80--
Other Assets0.401.202.230.790.770.470.030.000.01
Total Assets105.21124.43118.86137.84137.62276.57155.0934.7221.06
Short Term Debt Incl. Current Port. of LT Debt8.1511.064.968.749.2728.683.620.000.00
Accounts Payable11.2810.6010.3113.4810.9919.2511.642.302.12
Other Current Liabilities35.2241.4146.9546.8044.1961.5113.503.081.28
Total Current Liabilities54.6663.0662.2369.0264.44109.4428.765.373.39
Long Term Debt9.9511.8811.4521.6927.089.1311.900.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.200.250.761.38-11.151.80--
Other Liabilities5.1230.2716.706.401.809.2917.6222.264.24
Total Liabilities69.93105.4691.1498.4893.31139.0160.0827.637.64
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity35.2718.9727.7239.3644.31137.5795.027.0913.42
Total Shareholders Equity35.2718.9727.7239.3644.31137.5795.027.0913.42
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity35.2718.9727.7239.3644.31137.5795.027.0913.42
Total Liabilities & Stockholders Equity105.21124.43118.86137.84137.62276.57155.0934.7221.06
Book Value Per Share3.292.114.647.13459.40100.08151.0180.821,495.96
Tangible Book Value Per Share-0.57-2.59-4.14-3.55-272.94-9.9728.72-136.79229.39
Full-Time Employees7683102150164175755357
Price to Book Ratio0.550.390.530.220.581.001.881.510.74
Return on Assets-12.41-11.66-9.75-12.38-52.53-27.15-14.35-97.28-56.51
Return on Equity-52.55-60.76-37.33-39.91-119.62-50.12-26.68-264.54-116.94
Return on Invested Capital-31.51-43.97-40.45-27.93-152.38-39.73-12.74-382.80-75.89
Quick Ratio1.001.070.800.880.760.812.272.602.40
Current Ratio1.131.260.991.060.930.962.622.872.79

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-14.25-14.25-13.56-15.84-17.05-108.78-58.29-13.62-27.13
Depreciation3.933.935.386.728.8110.159.205.712.73
Other Funds (Non Cash)7.777.7711.9812.398.8180.6721.44-6.5910.78
Funds from Operations-2.55-2.553.803.270.58-17.96-27.64-14.50-13.62
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.835.83-5.73-4.66-5.80-10.861.68-13.88-0.21
Cash from Operating Activities3.283.28-1.94-1.39-5.22-28.82-25.96-28.37-13.83
Capital Expenditures-0.03-0.03-3.23-0.330.000.000.000.00-0.56
Net Assets From Acquisitions0.000.000.000.000.000.00-15.52-5.850.00
Sale of Fixed Assets and Businesses0.000.000.670.000.000.0015.720.390.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.12-3.25-3.02-0.20-0.51
Other Sources0.000.000.000.000.000.000.040.010.00
Cash from Investing Activities-0.03-0.03-2.56-0.33-0.12-3.25-2.78-5.66-1.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.0014.843.4715.5711.6940.1587.3214.08
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.0014.843.4715.5711.6940.1587.3214.08
Proceedsfrom Stock Options0.000.0014.843.4715.5711.6940.1560.33-1.48
Issuance or Reduction of Debt, Net-7.90-7.900.60-4.73-6.61-10.16-9.83-16.255.00
Change in Long Term Debt-4.91-4.91-6.07-5.56-4.36-6.04-9.83-16.255.00
Issuance of Long Term Debt0.000.001.8112.730.0014.4751.213.195.00
Reduction of Long Term Debt-4.91-4.91-7.87-18.29-4.36-20.51-61.03-19.440.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.01-0.010.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.01-0.010.000.00
Cash from Financing Activities-7.90-7.9015.44-1.268.961.5330.3171.0719.08
Net Change in Cash-4.64-4.6410.95-2.983.62-30.541.5737.044.18
Free Cash Flow3.253.25-2.17-1.72-5.22-28.82-25.96-28.37-14.39
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow12.788.14-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments26.3126.7130.0232.6330.9518.17
Short Term Receivables22.7824.4930.9233.2331.1635.83
Inventories6.867.468.6610.1011.4311.06
Other Current Assets5.818.666.645.155.647.46
Total Current Assets61.7667.3376.2481.1179.1872.51
Net Property, Plant & Equipment1.241.321.441.511.591.66
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets41.4042.4943.5841.4342.2048.71
Deferred Tax Assets0.40---0.25-
Other Assets0.400.560.740.941.201.32
Total Assets105.21111.69122.00124.99124.43124.20
Short Term Debt Incl. Current Port. of LT Debt8.1512.4711.1316.9311.0611.99
Accounts Payable11.2813.2114.2612.3410.6012.04
Other Current Liabilities35.2234.2940.1736.7241.4146.68
Total Current Liabilities54.6659.9765.5665.9963.0670.71
Long Term Debt9.9510.4710.9711.4711.8810.54
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.20---0.25-
Other Liabilities5.126.1131.2724.3530.278.06
Total Liabilities69.9376.55107.80101.82105.4689.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity35.2735.1414.2023.1718.9734.90
Total Shareholders Equity35.2735.1414.2023.1718.9734.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity35.2735.1414.2023.1718.9734.90
Total Liabilities & Stockholders Equity105.21111.69122.00124.99124.43124.20
Book Value Per Share3.293.271.322.342.115.66
Tangible Book Value Per Share-0.57-0.68-2.74-1.84-2.59-2.24
Full-Time Employees76---83-
Price to Book Ratio0.552.061.110.890.390.24
Return on Assets-12.41-28.93-20.62-11.05-11.660.85
Return on Equity-52.55-97.42-109.23-50.23-60.763.29
Return on Invested Capital-0.03-12.32-42.055.67-64.258.79
Quick Ratio1.001.001.031.081.070.87
Current Ratio1.131.121.161.231.261.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-0.01-5.62-10.581.97-19.823.99
Depreciation1.121.120.890.801.291.32
Other Funds (Non Cash)-0.392.139.39-3.3619.69-2.01
Funds from Operations0.72-2.37-0.31-0.591.163.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.69-1.813.98-0.021.64-9.76
Cash from Operating Activities4.41-4.183.67-0.622.80-6.46
Capital Expenditures-0.010.00-0.020.00-3.02-0.07
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.010.00-0.020.00-3.02-0.07
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.0014.840.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.0014.840.00
Proceedsfrom Stock Options0.000.000.000.0014.840.00
Issuance or Reduction of Debt, Net-4.800.87-6.262.30-1.854.30
Change in Long Term Debt-0.46-0.46-0.47-3.51-0.88-1.72
Issuance of Long Term Debt0.000.000.000.001.810.00
Reduction of Long Term Debt-0.46-0.46-0.47-3.51-2.69-1.72
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-4.800.87-6.262.3012.994.30
Net Change in Cash-0.41-3.31-2.601.6812.78-2.23
Free Cash Flow4.39-4.183.66-0.622.79-6.52
Price to Free Cash Flow12.7817.46----

Revenue breakdown

ADHD Portfolio2025: 57.58M 2026: 45.83M
E X X U A Portfolio2026: 6.57M
Product and Service, Other2025: 37.00K 2026: 36.00K
The Pediatric Portfolio2025: 8.77M 2026: 5.14M
United States2025: 66.38M 2026: 57.57M
Total Pharmaceutical Preparations revenue2025: 66.38M 2026: 57.57M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.03%0.3M10.0M35.46K
2026-10-153.30%0.3M10.0M34.78K
2026-09-303.47%0.3M10.0M34.69K
2026-09-153.17%0.3M9.8M27.01K
2026-08-313.40%0.3M9.8M27.97K
2026-08-143.27%0.3M9.8M31.60K
2026-07-313.38%0.3M9.6M36.54K
2026-07-153.55%0.3M9.8M36.61K
2026-06-303.57%0.3M9.8M39.42K
2026-06-153.63%0.4M9.8M42.86K
2026-05-294.18%0.4M9.8M45.24K
2026-05-154.69%0.5M9.8M44.51K
2026-04-305.17%0.5M9.8M46.39K
2026-04-155.14%0.5M9.8M56.51K
2026-03-315.18%0.5M9.7M77.84K
2026-03-135.23%0.5M9.7M95.35K
2026-02-274.85%0.5M9.7M94.36K
2026-02-134.67%0.5M9.7M97.67K
2026-01-305.62%0.5M9.8M93.39K
2026-01-155.87%0.5M9.3M93.50K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-10SEC
2026-09-2210-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-06-258-KCurrent report2026-06-23SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-04-028-KCurrent report2026-03-31SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-13SCHEDULE 13G/ASEC
2026-02-0310-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-038-KCurrent report2026-02-03SEC
2026-01-208-KCurrent report2026-01-20SEC
2025-12-108-KCurrent report2025-12-10SEC
2025-11-14SCHEDULE 13G/ASEC
2025-11-138-KCurrent report2025-11-13SEC
2025-11-12SCHEDULE 13G/ASEC
2025-10-24ARSAnnual report to security holders. 2025-06-30SEC
2025-10-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2025-10-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-10SEC
2025-10-205Annual statement of changes in beneficial ownership of securities2025-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC20.25%
Stonepine Capital Management, LLC8.51%
AWM Investment Company, Inc.5.77%
VANGUARD CAPITAL MANAGEMENT LLC2.43%
CROWN ADVISORS MANAGEMENT, INC.1.86%
DIADEMA PARTNERS LP1.38%
GEODE CAPITAL MANAGEMENT, LLC1.14%
TWO SIGMA INVESTMENTS, LP0.98%
RENAISSANCE TECHNOLOGIES LLC0.98%
DIMENSIONAL FUND ADVISORS LP0.46%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.57%
VANGUARD EXTENDED MARKET INDEX FUND0.86%
Fidelity Extended Market Index Fund0.45%
Fidelity Series Total Market Index Fund0.13%
Fidelity Total Market Index Fund0.09%
U.S. VECTOR EQUITY PORTFOLIO0.05%
Dimensional US Sustainability Core 1 ETF0.04%
U.S. Sustainability Core 1 Portfolio0.04%
Dimensional U.S. Small Cap ETF0.04%
Dimensional U.S. Core Equity 2 ETF0.04%

OakChart. AYTU. Cached 15 minutes.

Some panels did not load: insider.